SCHEMBL5135904

SCHEMBL5135904

CCCCN(Cc1ccc2c(c1)OCCO2)Cc1c(-c2ccc(OC)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.56
GNRHR P30968 7/20 0.44
ALDH1A1 P00352 3/20 0.38
MAPT P10636 3/20 0.38
KDM4E B2RXH2 2/20 0.38
HPGD P15428 2/20 0.38
GAA P10253 2/20 0.38
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
TP53 P04637 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
BCHE P06276 3/20 0.38
NPSR1 Q6W5P4 2/20 0.37
ATP4A P20648 2/20 0.37
ATP4B P51164 2/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134900 0.95 C5AR1 (0.63) C5AR1GNRHRALDH1A1MAPTKDM4E
SCHEMBL5135332 0.94 C5AR1 (0.59) C5AR1GNRHRALDH1A1MAPTKDM4E
SCHEMBL5135936 0.93 C5AR1 (0.63) C5AR1GNRHRALDH1A1MAPTKDM4E
SCHEMBL5071329 0.91 C5AR1 (0.60) C5AR1GNRHRALDH1A1MAPTKDM4E
SCHEMBL5136601 0.90 C5AR1 (0.58) C5AR1GNRHRMAPTGAASMN1; SMN2
SCHEMBL5073846 0.90 C5AR1 (0.58) C5AR1GNRHRALDH1A1MAPTKDM4E
SCHEMBL648955 0.90 C5AR1 (0.58) C5AR1GNRHRALDH1A1KDM4EHPGD
SCHEMBL5136554 0.90 C5AR1 (0.58) C5AR1GNRHRMAPTKDM4EGAA
SCHEMBL5135734 0.90 C5AR1 (0.63) C5AR1MAPTKDM4EGAASMN1; SMN2
SCHEMBL4768447 0.90 C5AR1 (0.64) C5AR1GNRHRALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed